<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975490</url>
  </required_header>
  <id_info>
    <org_study_id>ACLF-Initiative</org_study_id>
    <nct_id>NCT04975490</nct_id>
  </id_info>
  <brief_title>Characterization and Pathogenesis of ACLF</brief_title>
  <acronym>ACLF-I</acronym>
  <official_title>Beobachtungsstudie f√ºr Die Charakterisierung Der Pathogenese Des Akut-auf-chronischen Leberversagens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center prospective observational study aims at characterization of pathogenesis&#xD;
      of ACLF. There will be three different cohorts investigated with the main endpoint mortality&#xD;
      in these groups.&#xD;
&#xD;
        1. SAPIENT = Sepsis ACLF patients, to investigate the differences between ACLF and sepsis&#xD;
           in cirrhosis&#xD;
&#xD;
        2. PROACT = Portal mediators as ACLF Targets, to assess portal venous biomarkers in&#xD;
           patients receiving TIPS leading to ACLF and identify potential treatment targets&#xD;
&#xD;
        3. ELITE = prEdictors of beneficial LIver Tx in ACFL patiEnts, to assess in ACLF-patients&#xD;
           receiving liver transplantation predictors of survival, which may improve selection of&#xD;
           ACLF-patients for liver transplantation Secondary endpoints will be different in the&#xD;
           three different cohorts and biological material will be collected for separate ancillary&#xD;
           studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>number of patients</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>SAPIENT = Sepsis ACLF patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>PROACT = Portal mediators as ACLF Targets</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ELITE = prEdictors of beneficial LIver Tx in ACFL patiEnts</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with liver cirrhosis and complications&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  extrahepatic and metastatic malignancy,&#xD;
&#xD;
          -  refusal for participation&#xD;
&#xD;
          -  decision of attending phycisian&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonel Trebicka, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University Hospital Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonel Trebicka, MD, PhD</last_name>
    <phone>+4963014256</phone>
    <email>jonel.trebicka@kgu.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Translational Hepatology</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonel Trebicka</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Jonel Trebicka</investigator_full_name>
    <investigator_title>Principal Investigator and Coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

